We take a fresh look at Telix Pharmaceuticals, amid a multitude of potentially transformative developments, both strategically and financially. In the process, we update our intrinsic assessment, prior to incorporation of the recently announced USD 1.65 billion ITM Isotopes Technologies purchase.
Telix has had solid distribution of its PSMA agents, which will benefit its new products when they are approved.
R&D intensive spending is likely to continue, with no guarantee of success in commercializing new products.
|
Metric
|
TLX
|
VRTX
|
NVS
|
|---|---|---|---|
Price/Earnings (Normalized) | 92.98 | 26.63 | 13.57 |
Price/Book Value | 9.95 | 6.34 | 6.45 |
Price/Sales | 3.89 | 10.32 | 4.80 |
Price/Cash Flow | — | 26.17 | 14.16 |
|
Metric
|
TLX
|
VRTX
|
NVS
|
|---|---|---|---|
Quick Ratio | 1.74 | 2.54 | 0.55 |
Current Ratio | 2.01 | 3.19 | 0.86 |
Interest Coverage | 1.56 | — | 11.90 |
|
Metric
|
TLX
|
VRTX
|
NVS
|
|---|---|---|---|
Return on Assets (Normalized) | 2.08% | 18.99% | 14.74% |
Return on Equity (Normalized) | 6.42% | 26.29% | 39.06% |
Return on Invested Capital (Normalized) | 5.73% | 21.93% | 21.25% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vYpnJ$ | LOCK|R?Dp | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|t%bxmn | LOCK|&?HS$ | $76B | |||
| Moderna Inc
MRNA
| LOCK|mTk#<pZ | LOCK|tY | $75B | |||
| argenx SE ADR
ARGX
| LOCK|yWHCxq | LOCK|Wv | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bf!NjxL | LOCK|&!W | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&>jr<? | LOCK|Jf#$t | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|G&!mg#h% | LOCK|$nc% | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|MWK?@? | LOCK|#l& | $24B | |||
| Incyte Corp
INCY
| LOCK|<DM<&d | LOCK|k%% | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@XKhV$l | LOCK|^kw | $15B |
United States